OSI Systems, NVE, Biodexa Pharmaceuticals, Clene, and Virpax Pharmaceuticals are the five Nanotechnology stocks to watch today, according to MarketBeat's stock screener tool. Error: Response status code does not indicate success: 429 (Too Many Requests). These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.
OSI Systems (OSIS)
OSI Systems, Inc. designs and manufactures electronic systems and components. It operates in three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The Security segment offers baggage and parcel inspection, cargo and vehicle inspection, hold baggage and people screening, radiation monitoring, explosive and narcotics trace detection systems, and optical inspection systems under the Rapiscan name.
Shares of OSI Systems stock traded down $2.69 during trading on Monday, hitting $198.99. The stock had a trading volume of 80,581 shares, compared to its average volume of 242,863. The firm has a market cap of $3.34 billion, a price-to-earnings ratio of 25.64, a P/E/G ratio of 1.81 and a beta of 1.19. The company has a current ratio of 1.88, a quick ratio of 1.25 and a debt-to-equity ratio of 0.56. The business's 50-day moving average is $192.59 and its 200 day moving average is $177.80. OSI Systems has a 12 month low of $129.18 and a 12 month high of $220.00.
Read Our Latest Research Report on OSIS
NVE (NVEC)
NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on electron spin to acquire, store, and transmit information in the United States and internationally. The company manufactures spintronic products, including sensors and couplers for use in acquiring and transmitting data.
NVE stock traded down $0.60 during mid-day trading on Monday, hitting $57.88. 10,968 shares of the company traded hands, compared to its average volume of 22,399. NVE has a one year low of $51.50 and a one year high of $89.98. The stock has a fifty day moving average price of $63.50 and a 200-day moving average price of $72.73. The stock has a market cap of $279.94 million, a price-to-earnings ratio of 18.67 and a beta of 1.05.
Read Our Latest Research Report on NVEC
Biodexa Pharmaceuticals (BDRX)
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.
Shares of BDRX traded down $0.08 during midday trading on Monday, reaching $1.48. The stock had a trading volume of 71,099 shares, compared to its average volume of 1,501,021. Biodexa Pharmaceuticals has a 12-month low of $1.14 and a 12-month high of $74.00. The company's 50-day moving average is $2.11 and its 200 day moving average is $3.88.
Read Our Latest Research Report on BDRX
Clene (CLNN)
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
CLNN traded down $0.05 during midday trading on Monday, hitting $2.96. The stock had a trading volume of 26,733 shares, compared to its average volume of 58,126. The company has a market cap of $25.40 million, a P/E ratio of -0.56 and a beta of 0.46. Clene has a 1 year low of $2.57 and a 1 year high of $9.20. The business has a fifty day moving average of $3.67 and a 200 day moving average of $4.50.
Read Our Latest Research Report on CLNN
Virpax Pharmaceuticals (VRPX)
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.
Shares of VRPX stock traded up $0.01 on Monday, hitting $0.26. 18,018 shares of the company's stock traded hands, compared to its average volume of 321,650. The company's fifty day simple moving average is $2.58 and its 200 day simple moving average is $8.16. Virpax Pharmaceuticals has a one year low of $0.13 and a one year high of $84.75.
Read Our Latest Research Report on VRPX
See Also
Before you consider OSI Systems, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OSI Systems wasn't on the list.
While OSI Systems currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
